Moore Capital Management Acquires Stake in Bio-Rad Laboratories

Hedge fund buys 55,000 shares of medical research company

Mar. 17, 2026 at 10:52am

Got story updates? Submit your updates here. ›

Moore Capital Management LP, a prominent hedge fund, has acquired a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO), purchasing 55,000 shares of the medical research company's stock during the third quarter, according to a recent SEC filing.

Why it matters

The acquisition of a significant stake in Bio-Rad Laboratories by a major hedge fund like Moore Capital Management suggests the fund sees potential in the company's future performance and growth prospects. This could signal increased investor interest and confidence in Bio-Rad's business.

The details

According to the SEC filing, Moore Capital Management purchased 55,000 shares of Bio-Rad Laboratories, valued at approximately $15.4 million. This represents a 0.20% ownership stake in the company. Bio-Rad Laboratories is a global provider of life science research and clinical diagnostic products, operating in the Life Science and Clinical Diagnostics segments.

  • The shares were acquired during the third quarter of the year.

The players

Moore Capital Management LP

A prominent hedge fund that has acquired a new position in Bio-Rad Laboratories.

Bio-Rad Laboratories, Inc.

A global provider of life science research and clinical diagnostic products, operating in the Life Science and Clinical Diagnostics segments.

Got photos? Submit your photos here. ›

The takeaway

The acquisition of a significant stake in Bio-Rad Laboratories by a major hedge fund like Moore Capital Management suggests increased investor confidence in the company's future prospects and growth potential within the medical research and diagnostics industry.